ATE228848T1 - Il-6 enthaltende pharmazeutische zusammensetzungen ihre verfahren zur behandlungder verbrauchenden hämorrhagischen thrombozythämie - Google Patents

Il-6 enthaltende pharmazeutische zusammensetzungen ihre verfahren zur behandlungder verbrauchenden hämorrhagischen thrombozythämie

Info

Publication number
ATE228848T1
ATE228848T1 AT93915854T AT93915854T ATE228848T1 AT E228848 T1 ATE228848 T1 AT E228848T1 AT 93915854 T AT93915854 T AT 93915854T AT 93915854 T AT93915854 T AT 93915854T AT E228848 T1 ATE228848 T1 AT E228848T1
Authority
AT
Austria
Prior art keywords
pct
methods
pharmaceutical compositions
compositions containing
consumable
Prior art date
Application number
AT93915854T
Other languages
English (en)
Inventor
Armaud Ythier
Jean-Claude Mestries
Francis Herodin
Serge Martin
Original Assignee
Applied Research Systems
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB929214489A external-priority patent/GB9214489D0/en
Priority claimed from GB939301251A external-priority patent/GB9301251D0/en
Application filed by Applied Research Systems filed Critical Applied Research Systems
Application granted granted Critical
Publication of ATE228848T1 publication Critical patent/ATE228848T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/204—IL-6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2066—IL-10
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT93915854T 1992-07-08 1993-07-08 Il-6 enthaltende pharmazeutische zusammensetzungen ihre verfahren zur behandlungder verbrauchenden hämorrhagischen thrombozythämie ATE228848T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB929214489A GB9214489D0 (en) 1992-07-08 1992-07-08 Pharmaceutical compositions and uses therefor
GB939301251A GB9301251D0 (en) 1993-01-22 1993-01-22 Pharmaceutical compositions and use therefor
PCT/EP1993/001790 WO1994001123A1 (en) 1992-07-08 1993-07-08 Pharmaceutical composition containing il-6, their uses for the treatment of consumptive thrombo-hemorrhagic disorder

Publications (1)

Publication Number Publication Date
ATE228848T1 true ATE228848T1 (de) 2002-12-15

Family

ID=26301225

Family Applications (1)

Application Number Title Priority Date Filing Date
AT93915854T ATE228848T1 (de) 1992-07-08 1993-07-08 Il-6 enthaltende pharmazeutische zusammensetzungen ihre verfahren zur behandlungder verbrauchenden hämorrhagischen thrombozythämie

Country Status (13)

Country Link
US (1) US5925344A (de)
EP (1) EP0651648B1 (de)
JP (1) JP3845112B2 (de)
AT (1) ATE228848T1 (de)
AU (1) AU674864B2 (de)
CA (1) CA2139353C (de)
DE (1) DE69332541T2 (de)
DK (1) DK0651648T3 (de)
ES (1) ES2183814T3 (de)
IL (1) IL106272A (de)
MX (1) MX9304075A (de)
PT (1) PT651648E (de)
WO (1) WO1994001123A1 (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7108982B1 (en) 1999-02-19 2006-09-19 University Of Iowa Research Foundation Diagnostics and the therapeutics for macular degeneration
JP2003506016A (ja) * 1999-02-19 2003-02-18 ザ ユニヴァーシティー オブ アイオワ リサーチ ファンデーション 動脈壁破裂障害のための診断剤および治療剤
EP1066834A3 (de) * 1999-07-08 2004-06-02 Thomas Dr. Stief Pharmazeutische Zusammensetzungen enthaltend ein phagozytenmodulierendes Agens
WO2002015882A1 (en) * 2000-08-24 2002-02-28 Lytone Enterprise, Inc. Delayed release compositions and combinations
FI20041425A0 (fi) * 2004-11-05 2004-11-05 Orion Corp Transmukosaalinen veterinäärinen koostumus
AU2010306581B2 (en) * 2009-10-16 2015-03-19 Omeros Corporation Methods for treating disseminated intravascular coagulation by inhibiting MASP-2 dependent complement activation
US9644035B2 (en) 2011-04-08 2017-05-09 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
RU2477530C2 (ru) * 2011-04-28 2013-03-10 Общество С Ограниченной Ответственностью "Научно-Производственная Фирма "Материа Медика Холдинг" Способ коррекции эндотелиальной дисфункции раствором гомеопатических разведений антител к интерлейкину-6

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5271931A (en) * 1988-09-14 1993-12-21 The Scripps Research Institute Methods for increasing C1 inhibitor concentrations using interferon-gamma and/or interleukin-6
JPH0372429A (ja) * 1988-10-07 1991-03-27 Chugai Pharmaceut Co Ltd 血小板減少症の治療剤
JP2805224B2 (ja) * 1989-01-13 1998-09-30 味の素株式会社 血小板減少症治療剤
US5087448A (en) * 1989-02-02 1992-02-11 The Board Of Regents Of The University Of Oklahoma Enhancing growth of megakaryocytes in mammals using interleuking 6
JPH04218000A (ja) * 1990-02-13 1992-08-07 Kirin Amgen Inc 修飾ポリペプチド
US5188828A (en) * 1990-11-08 1993-02-23 Brigham And Women's Hospital Interleukin-6 to stimulate erythropoietin production
WO1992008483A1 (en) * 1990-11-13 1992-05-29 The Children's Medical Center Corporation CONTROLLING β-AMYLOID RELATED NEURONAL DEGENERATION BY ANTAGONIZING NGF-EFFECTED NEURONAL ACTIVITY
EP0560998A4 (en) * 1991-10-09 1993-12-01 Toray Industries, Inc. Medicine for preventing and treating bleeding tendency

Also Published As

Publication number Publication date
DE69332541D1 (de) 2003-01-16
JP3845112B2 (ja) 2006-11-15
EP0651648A1 (de) 1995-05-10
AU4566493A (en) 1994-01-31
CA2139353C (en) 2006-11-07
EP0651648B1 (de) 2002-12-04
IL106272A (en) 1999-01-26
CA2139353A1 (en) 1994-01-20
ES2183814T3 (es) 2003-04-01
AU674864B2 (en) 1997-01-16
WO1994001123A1 (en) 1994-01-20
IL106272A0 (en) 1993-11-15
MX9304075A (es) 1994-04-29
DK0651648T3 (da) 2003-01-06
US5925344A (en) 1999-07-20
PT651648E (pt) 2003-04-30
JPH08502028A (ja) 1996-03-05
DE69332541T2 (de) 2003-04-17

Similar Documents

Publication Publication Date Title
DE69017302D1 (de) Zentrale Cholecystokinin-Antagonisten zur Behandlung von psychiatrischen Krankheiten.
DE69230112D1 (de) Fortschrittliches arzneistoffabgabesystem und verfahren zur behandlung von psychiatrischen, neurologischen und anderen erkrankungen mit carbamazepin
ES2166111T3 (es) Uso de tiagabina para el tratamiento de trastornos del sueño.
DE69317578D1 (de) Verwendung von riluzole zur behandlung von traumatischen neurologischen-schädigungen
SE9604793L (sv) Nya Kristallmodifikationer
EE9900465A (et) Uued ühendid
EE200000318A (et) Uudsed ühendid
DE69531741D1 (de) Verbindungen und zusammensetzungen zur verabreichung aktiver stoffe
NZ504026A (en) Methods for treating hypercoagulable states or acquired protein C deficiency using human-activated protein C
DE69326776D1 (de) Verwendung von n-arylmethylen ethylendiamintriacetate, n-arylmethylen iminodiacetat oder n,n'-diarylmethylen ethylendiamindiacetat gegen oxidativen stress
ZA946142B (en) Therapeutic heterocycles
ATE211384T1 (de) Verwendung von adenosinantagonisten zur vorbeugung und behandlung von pankreatitis und ulcera
DK1545537T3 (da) Alfa-7-nikotinreceptoragonister og statiner i kombination
BR9406689A (pt) Adenovirus recombinante defectivo utilização deste adenovirus e composição farmacêutica obtida
IL101358A0 (en) Crystalline tiagabine hydrochloride monohydrate,its preparation and pharmaceutical compositions containing it
DK0613499T3 (da) Humame IT-4-mutantproteiner
DE69332541D1 (de) Il-6 enthaltende pharmazeutische zusammensetzungen ihre verfahren zur behandlungder verbrauchenden hämorrhagischen thrombozythämie
ATE161423T1 (de) Verwendung von phosphinate zur behandlung der osteoporose
ATE104551T1 (de) S-adenosylmethionin zur behandlung von pankreatitis und der immunabstossung des pankreastransplantates.
ATE214939T1 (de) Behandlung von neurologischen zuständen durch eine interleukin-i-inhibierende verbindung
PT706395E (pt) Uso de ropivacaina na preparacao duma composicao farmaceutica com efeito analgesico e bloqueio motor minimo
CZ157795A3 (en) Pharmaceutical preparations for treating prostatitis
ATE194775T1 (de) Calcitonin enthaltende pharmazeutische zusammensetzungen
SE9303068D0 (sv) New use
DE69927599D1 (de) Verwendung von wachstumshormon und analoga davon für die behandlung von säugern mit familiärer hypercholesterolämie

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0651648

Country of ref document: EP

REN Ceased due to non-payment of the annual fee